Literature DB >> 19903146

The Yin and Yang of CD4(+) regulatory T cells in autoimmunity and cancer.

M Galgani1, A Di Giacomo, G Matarese, A La Cava.   

Abstract

The immune system balances effector responses with tolerance, to protect the host from pathogens while minimizing local damage to tissue. An altered control of immune homeostasis can lead to loss of tolerance to self antigens in autoimmunity, or promote unwanted tolerance to tumor growth. This review focuses on the dual activity of CD4(+) regulatory T cells (Tregs) in autoimmunity and cancer. Tregs play a key role in the mechanisms of immune tolerance and actively suppress pro-inflammatory responses, thus providing a beneficial action in autoimmunity and detrimental effects in cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903146     DOI: 10.2174/092986709789878201

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

Review 1.  Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.

Authors:  Geetha Mathew; M K Unnikrishnan
Journal:  Inflamm Res       Date:  2015-07-18       Impact factor: 4.575

2.  Protective HIV-specific CD8+ T cells evade Treg cell suppression.

Authors:  Shokrollah Elahi; Warren L Dinges; Nicholas Lejarcegui; Kerry J Laing; Ann C Collier; David M Koelle; M Juliana McElrath; Helen Horton
Journal:  Nat Med       Date:  2011-07-17       Impact factor: 53.440

3.  The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.

Authors:  Qing Yan
Journal:  Methods Mol Biol       Date:  2022

4.  Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Authors:  Shanna A Arnold; Lee B Rivera; Juliet G Carbon; Jason E Toombs; Chi-Lun Chang; Amy D Bradshaw; Rolf A Brekken
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

Review 5.  The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer.

Authors:  Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Clin Dev Immunol       Date:  2013-12-28

6.  Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice.

Authors:  Zhengquan Feng; Wanrong Hao; Xiaoyang Lin; Daping Fan; Juhua Zhou
Journal:  Onco Targets Ther       Date:  2014-06-09       Impact factor: 4.147

7.  Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia.

Authors:  Mau-Shin Chi; Minesh P Mehta; Kai-Lin Yang; Hung-Chih Lai; Ying-Chu Lin; Hui-Ling Ko; Yu-Shan Wang; Kuang-Wen Liao; Kwan-Hwa Chi
Journal:  Front Oncol       Date:  2020-03-10       Impact factor: 6.244

8.  Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

Authors:  Emmet McCormack; Katherine J Adams; Namir J Hassan; Akhil Kotian; Nikolai M Lissin; Malkit Sami; Maja Mujić; Tereza Osdal; Bjørn Tore Gjertsen; Deborah Baker; Alex S Powlesland; Milos Aleksic; Annelise Vuidepot; Olivier Morteau; Deborah H Sutton; Carl H June; Michael Kalos; Rebecca Ashfield; Bent K Jakobsen
Journal:  Cancer Immunol Immunother       Date:  2012-12-22       Impact factor: 6.968

9.  Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6.

Authors:  Joonhee Cho; Lina Kim; Zhaoxia Li; Noel R Rose; Monica Vladut Talor; Dolores B Njoku
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.

Authors:  Anthony Park; Chindu Govindaraj; Sue D Xiang; Julene Halo; Michael Quinn; Karen Scalzo-Inguanti; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2012-06-18       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.